← FDA DRUG APPROVALS

FDA ANDA · ANDA207355

POSACONAZOLE

Sponsor: ACTAVIS LABS FL INC

APPLICATION
ANDA207355
TYPE
ANDA
ORIGINAL APPROVAL
2022-11-30
LATEST ACTION
2022-11-30
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

POSACONAZOLEDiscontinued
POSACONAZOLE 100MG · TABLET, DELAYED RELEASE · ORAL

Approval history

2022-11-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →